Technical Analysis for ARDM - Aradigm Corp

Grade Last Price % Change Price Change
grade D 0.12 -73.91% -0.3400
ARDM closed down 73.91 percent on Tuesday, February 19, 2019, on 9.14 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical ARDM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Volume Surge Other 0.00%
Wide Range Bar Range Expansion 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Older signals for ARDM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. Its lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as Coxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague. Aradigm Corporation has collaboration agreements with Grifols, S.A. The company was founded in 1991 and is headquartered in Hayward, California. On February 15, 2019, Aradigm Corporation filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of California.
Medical Specialties RTT Pharmaceutical U.S. Bankruptcy Court Infectious Diseases Cystic Fibrosis Infections Bacterial Diseases Zoonoses Bioterrorism Bronchiectasis Non Cystic Fibrosis Bronchiectasis Tularemia

Is ARDM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.8001
52 Week Low 0.0701
Average Volume 59,202
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.5208
10-Day Moving Average 0.4592
Average True Range 0.1173
ADX 0.0
+DI 19.5598
-DI 36.3941
Chandelier Exit (Long, 3 ATRs ) 0.4482
Chandelier Exit (Short, 3 ATRs ) 0.4220
Upper Bollinger Band 0.7397
Lower Bollinger Band 0.3019
Percent B (%b) -0.42
BandWidth 84.0630
MACD Line -0.0821
MACD Signal Line -0.0356
MACD Histogram -0.0465
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.5399
Resistance 3 (R3) 0.5699 0.4599 0.4699
Resistance 2 (R2) 0.4599 0.3530 0.4449 0.4465
Resistance 1 (R1) 0.2900 0.2870 0.2350 0.2600 0.4232
Pivot Point 0.1800 0.1800 0.1526 0.1650 0.1800
Support 1 (S1) 0.0101 0.0731 -0.0449 -0.0200 -0.1832
Support 2 (S2) -0.0999 0.0071 -0.1149 -0.2065
Support 3 (S3) -0.2698 -0.0999 -0.2299
Support 4 (S4) -0.2999